The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review

Levomilnacipran, the more active enantiomer of the serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in the US for the treatment of major depressive disorder (MDD). The drug was developed as an extended release (ER) capsule formulation to allow for once-daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Antonio, Morabito, Paolo, Spina, Edoardo, Muscatello, Maria Rosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825949/
https://www.ncbi.nlm.nih.gov/pubmed/26572745
http://dx.doi.org/10.2174/1570159X14666151117122458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825949/
https://www.ncbi.nlm.nih.gov/pubmed/26572745
http://dx.doi.org/10.2174/1570159X14666151117122458

Ejemplares similares